Eli Lilly’s weight loss drug Zepbound could avert up to 627,000 atrial fibrillation cases by 2030, according to Airfinity analysts.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
Zepbound could prevent 600K AFib cases by 2030: Report
